Evidence map›Paper›PMID 40815612›Full record

ArticleHuman molecular genetics2025

Refining rare disease variant discovery in an isolated Andean community through imputation-enhanced IBD and kinship inference from whole exome sequencing data.

Cristian Camilo Gaviria-Sabogal, Ingrid Tatyana Bernal, Yasmín Sánchez-Gómez, William Usaquén, Andrea Casas-Vargas, Nora Contreras Bravo, Adrien Morel, Dora J Fonseca-Mendoza, Carlos M Restrepo, Rodrigo Cabrera

Abstract read
In one paragraph

Article in Human molecular genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Cristian Camilo Gaviria-SabogalSchool of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Universidad del Rosario, Carrera 24 No. 63C-69, Bogotá D.C. 111221, Colombia.
Ingrid Tatyana BernalUniversidad Nacional de Colombia, Calle 53 No. 37A-47, Bogotá D.C. 111321, Colombia.
Yasmín Sánchez-GómezUniversidad de Boyacá. Medisens IPS, Carrera 1F No. 39-76, Tunja, Boyacá, 150003, Colombia.
William UsaquénGrupo de Genética de Poblaciones e Identificación. Institute of Human Genetics, Universidad Nacional de Colombia, Calle 53 No. 37A-47, Bogotá D.C. 111321, Colombia.
Andrea Casas-VargasGrupo de Genética de Poblaciones e Identificación. Institute of Human Genetics, Universidad Nacional de Colombia, Calle 53 No. 37A-47, Bogotá D.C. 111321, Colombia.
Nora Contreras BravoSchool of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Universidad del Rosario, Carrera 24 No. 63C-69, Bogotá D.C. 111221, Colombia.
Adrien MorelSchool of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Universidad del Rosario, Carrera 24 No. 63C-69, Bogotá D.C. 111221, Colombia.
Dora J Fonseca-MendozaSchool of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Universidad del Rosario, Carrera 24 No. 63C-69, Bogotá D.C. 111221, Colombia.
Carlos M RestrepoSchool of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Universidad del Rosario, Carrera 24 No. 63C-69, Bogotá D.C. 111221, Colombia.
Rodrigo CabreraSchool of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Universidad del Rosario, Carrera 24 No. 63C-69, Bogotá D.C. 111221, Colombia.ORCID 0000-0002-5731-1788

Funding

Ministry of Science, Technology, and Innovation 632-2021Ministry of Science, Technology, and Innovation November 2021Universidad del Rosario QAN BG273Universidad Nacional de Colombia
6 · The paper itself

Abstract

Rare genetic diseases pose significant diagnostic challenges, especially in geographically isolated populations where consanguinity, founder effects, and novel variants often influence disease patterns. Whole-exome sequencing (WES) is standard practice for rare disease diagnostics, but its limited coverage of noncoding regions limits inheritance-by-descent (IBD) and Runs of Homozygosity (RoH) inference. In this study, we tested an imputation-enhanced IBD and RoH detection method using WES data of 84 individuals from 51 families in Boyacá, Colombia-an Andean region with complex admixed American ancestry. By leveraging large, multi-ancestry reference panels to impute genotypes and increase variant distribution, we achieved improved detection of IBD and RoH regions, with KING showing the best results among the different tools that were tested. Imputation with the 1000 Genome reference panel underperformed compared to raw WES data, whereas large reference panels with diverse ancestry showed the best performance. By integrating these refined IBD results with pedigree information, we identified cryptic family relationships, clarified the role of consanguinity, and improved the prioritization of candidate variants. Our findings show that imputation-enhanced IBD analyses can bolster the utility of WES for rare disease studies, contributing to more accurate and timely genetic diagnoses.

Indexed as

Exome SequencingRare DiseasesColombiaConsanguinityExomeFemaleGenetic Predisposition to DiseaseGenotypeHomozygoteHumansMalePedigreePolymorphism, Single NucleotideConsanguinityGenotype imputationIdentity-by-descentKinship inferenceUndiagnosed rare diseases

Identifiers

PMID40815612
PMCPMC12498279

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.